Tools To Help You With Treatment Decisions

After receiving a melanoma diagnosis, you will be presented with a lot of information, testing recommendations, and—if you’re diagnosed with a later stage melanoma—treatment options. So that you and your healthcare team can make the best decisions for you, it will be important to understand your risk of recurrence, to know all of your treatment options, and to learn specifics about each treatment. To assist you, AIM has created the following support tools.

Options for Stage III Melanoma: Making the Decision That’s Right for You

AIM’s guide, Options for Stage III Melanoma: Making the Decision That’s Right for You, is written for Stage III patients, to help explain what treatment options are available. The booklet begins by providing an in-depth discussion of why Stage III patients are at high risk for a melanoma recurrence and why treatment should be considered. It continues with a discussion of the treatment options available for Stage III patients, followed by information about how the drugs work and their side effects. The booklet also discusses other considerations such as fertility, finances, and drug administration. Finally, this guide provides a chart to help weigh the different options and, ultimately, make the treatment decision.

Is Immunotherapy Working for Me? What a Blood Draw Can Reveal

A new blood test is available for Stage IV patients that can help assess whether immunotherapy treatment is working and therefore help guide decisions about treatment. This booklet explains how the test works, gives examples of how the test might help guide treatment decisions, and offers an FAQ section that answers financial questions.

BRAF in Melanoma: Answering Questions, Addressing Misconceptions

This booklet is for Stage III and IV patients, as well as certain Stage II patients. It explains what BRAF is, why BRAF status matters, and how the BRAF test is performed. It also explains how BRAF status relates to treatment decisions.

Side Effect Management Guides

In partnership with leading melanoma oncology experts, AIM has developed comprehensive and up-to-date information on the side effects of commonly used melanoma treatments currently approved by the U.S. Food and Drug Administration.

Download or flip through the following patient-friendly side melanoma side effect management guides:

BRAFTOVI™ (encorafenib)/MEKTOVI® (binimetinib)
COTELLIC® (cobimetinib)/ZELBORAF® (vemurafenib)
IMLYGIC® (talimogene laherparepvec; T-VEC)
KEYTRUDA® (pembrolizumab)
OPDIVO® (nivolumab)
OPDIVO® (nivolumab)/YERVOY® (ipilimumab)
TAFINLAR® (dabrafenib)/MEKINIST® (trametinib)
YERVOY® (ipilimumab)